[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363040-105":59,"doc-detail-363040-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","optimizing-axillary-lymph-node-management-in-early-stage-hrher2-breast-cancer-practical-strategies-for-enhanced-detection-rates","Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer - Practical strategies for enhanced detection rates","","Abemaciclib is a globally approved adjuvant standard for HR+/HER2-high-risk early breast cancer, and improved outcomes depend on accurately defining nodal involvement and selecting high-risk patients. With methods and evaluation timepoints for involved axillary lymph nodes remaining unclear, a virtual medical advisory board convened in November 2023 to address gaps created by locoregional de-escalation. Recommendations cover pragmatic axillary evaluation, expeditious postdiagnosis assessment, and a diagnostic algorithm. Optimized staging supports identification of patients eligible for CDK4/6 inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/optimizing-axillary-lymph-node-management-in-early-stage-hrher2-breast-cancer-practical-strategies-for-enhanced-detection-rates/363040/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/optimizing-axillary-lymph-node-management-in-early-stage-hrher2-breast-cancer-practical-strategies-for-enhanced-detection-rates/363040.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is nodal involvement considered an adverse prognostic factor in early breast cancer?","Question",{"text":112,"@type":113},"Nodal involvement strongly influences prognosis in early breast cancer, making accurate evaluation essential for guiding treatment decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the purpose of the virtual medical advisory board meeting in November 2023?",{"text":117,"@type":113},"The panel discussed how changes in axillary management create knowledge gaps for identifying eligible patients for adjuvant CDK4/6 inhibitors, then aligned on recommendations to address these gaps.",{"name":119,"@type":110,"acceptedAnswer":120},"How should axillary lymph nodes be evaluated according to the recommendations?",{"text":121,"@type":113},"Axillary lymph node evaluation should be performed expeditiously after diagnosis and before neoadjuvant treatment, and pragmatic, less invasive approaches such as ultrasound and clinical assessment may be used.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363040,1790790283,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","The Breast 87 (2026) 104763  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Optimizing axillary lymph node management in early-stage HR+/HER2-breast cancer: Practical strategies for enhanced detection rates |  | |\n| --- | --- | --- |\n| Marc Thill a,* , Maria-Jo˜ao Cardoso b,c, Carmen Criscitiellod,e, Christian Kurzeder f, Giancarlo Prunerig, Fabian Riedel h, Jos´e Angel García-S´aenzi, Maria Vidalj, Andr´e Mattark, Stefanie Srock l, Anna Emdel, Monique Coersmeyer l, Michael Gnant m,n\u003Cbr>a Department of Gynaecology and Gynecologic Oncology, Breast Cancer Centre, Agaplesion Markus Hospital, Frankfurt, Germany b Champalimaud Foundation Breast Unit, Lisbon, Portugal\u003Cbr>c University of Lisbon, Faculty of Medicine, Lisbon, Portugal\u003Cbr>d Div of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy e Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy\u003Cbr>f Breast Cancer Center, University Hospital Basel, Basel, Switzerland\u003Cbr>g Department of Advanced Diagnostics, Fondazione IRCCS, Istituto Nazionale Tumori, Milan and University of Milan, School of Medicine, Milan, Italy h Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany\u003Cbr>i Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigaci´on Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain j Medical Oncology Department of Medical Oncology, Hospital Clinic, Barcelona, Spain\u003Cbr>k Women's Hospital – SP, S˜ao Paulo, Brazil l Eli Lilly and Company Ltd, Indianapolis, USA\u003Cbr>m Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austrian Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria |  |  |\n| A R T I C L E I N F O\u003Cbr>Keywords: Axilla Abemaciclib\u003Cbr>Breast cancer Early Lymph node Adjuvant | A B S T R A C T\u003Cbr>Introduction: Abemaciclib is a globally approved, standard-of-care adjuvant treatment for HR+/HER2-high-risk EBC which significantly improved outcomes in combination with ET, versus ET alone, in the pivotal monarchE trial. Nodal involvement is a major adverse prognostic factor in EBC; however, clarity around methods and timepoints for evaluation of involved ALNs and identification of high-risk patients eligible for adjuvant therapy is currently lacking.\u003Cbr>Methods: A medical advisory board met virtually in November 2023 to discuss the changing landscape of axillary management in early breast cancer. The discussion assessed the knowledge gap caused by locoregional deescalation for patients with HR+/HER- EBC leading to challenges in the appropriate identification of eligible patients for adjuvant CDK4/6 inhibitors. The panel aligned on recommendations to address these gaps and summarized these with the intent to raise awareness.\u003Cbr>Results: Positive lymph node status can be denoted by pathological or clinical confirmation of breast cancer in ALNs. The panel therefore agreed that pragmatic strategies for ALN evaluation may include less invasive approaches such as ultrasound and clinical assessment. Evaluation of ALNs should be performed expeditiously postdiagnosis and before neoadjuvant treatment. A diagnostic algorithm has been developed to guide clinicians. Conclusion: Optimized staging and risk assessment in HR+/HER2- EBC is critical to identify high-risk patients eligible for CDK4/6 inhibitors. Implementing these recommendations may improve patient outcomes in theadjuvant setting. |  |\n\n1. Introduction  \nBreast cancer is one of the most commonly diagnosed cancers  \nglobally [1]. Early-stage breast cancer (EBC), defined as cancer localized to the breast or confined to the regional lymph nodes, constitutes roughly 90% of all cases [2]. Approximately 70% of these are of the  \n* Corresponding author. Department of Gynecology and Gynecologic Onco","cbCaikhxPnHDLvXz","https://ap.wps.com/l/cbCaikhxPnHDLvXz","pdf",1920971,12,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"Why is nodal involvement considered an adverse prognostic factor in early breast cancer?\",\"answer\":\"Nodal involvement strongly influences prognosis in early breast cancer, making accurate evaluation essential for guiding treatment decisions.\"},{\"question\":\"What was the purpose of the virtual medical advisory board meeting in November 2023?\",\"answer\":\"The panel discussed how changes in axillary management create knowledge gaps for identifying eligible patients for adjuvant CDK4/6 inhibitors, then aligned on recommendations to address these gaps.\"},{\"question\":\"How should axillary lymph nodes be evaluated according to the recommendations?\",\"answer\":\"Axillary lymph node evaluation should be performed expeditiously after diagnosis and before neoadjuvant treatment, and pragmatic, less invasive approaches such as ultrasound and clinical assessment may be used.\"}]","Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer - Practical strategies for enhanced detection rates | PDF",1790149747,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f96e9bb39042a776ecc1cb7a5598615.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96964f1d286a1fab106442add79f2c25.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/432c9f383f7ff1b81f0dcd211e350881.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f3a89e3ff5742120ccf28335dbd170d.webp",980,1306]